You must select a location to proceed.
There was a problem adding this course to your account. Please try again in a few minutes. If the problem persists, you can contact our support department at (877) 880-1335.
Adding Registration, Please wait...
You must be logged in to perform this action.
Expires: 06/30/2021 (subject to change)
- CE for this activity will not be available after this date.
Delivery Note: The content for this activity is available in multiple delivery formats (OnDemand Video and Publication) in the AANP CE Center. Learners completing this activity should only complete ONE delivery-method to earn credit. Completing multiple delivery options for the same activity is duplicate credit for the same content and may not be accepted by some regulatory bodies.
Migraine is a considerable cause of morbidity and health care resource utilization with more than 1 billion people suffering from migraines worldwide. Migraine is much more than a bad headache and medication overuse is the #1 reason episodic migraines become chronic. Dr. Calli Cook, DNP, APRN, FNP-C will lead you through the diagnostic criteria for episodic and chronic migraine, the pathophysiology of a migraine including the pathogenic role of calcitonin gene-related peptide (CGRP), and how inhibition of CGRP can prevent and treat episodic and chronic migraine.
CE Credit Instructions
- Read this activity description, including objectives and disclosures.
- Complete the educational content completely:
- Video Presentations: Watch all video presentations completely.
- Publications: Read all pages of the attached publication documents.
- Review all additional materials provided (handouts, posttest reviews, any other downloadable resources).
- After completing all content, go to Steps to Receive Credit:
- Complete the posttest
- Submit the evaluation to receive full AANP CE/Rx credit.
- Describe the signs and symptoms of migraine as well as the diagnostic criteria for episodic and chronic migraine
- Explain the pathophysiology of migraine, including the pathogenic role of calcitonin gene-related peptide (CGRP)
- Explain how inhibition of CGRP can prevent and treat episodic and chronic migraine
- Assess the clinical efficacy and safety data surrounding new and emerging CGRP-targeted therapies
Calli Cook, DNP, APRN, FNP-C
This program was planned in accordance with AANP CE Standards and Policies.
Dr. Cook discloses the following affiliations: MIND advisory board; speaker’s bureau- Allergan.
AANP planners have no relevant financial relationships to disclose.This activity is supported by educational funding provided by Amgen.
Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
For questions or more information concerning this online CE opportunity contact the AANP CE Center Manager at CECenter@aanp.org.
|1 Contact Hour(s) of CE,
0.5 of which may be applied towards Pharmacology
Additional CE activities of interest
Improving Diagnosis and Care of Primary Headache Disorders With New Targeted Therapies